275 related articles for article (PubMed ID: 27203221)
1. Aptamer-guided DNA tetrahedron as a novel targeted drug delivery system for MUC1-expressing breast cancer cells in vitro.
Dai B; Hu Y; Duan J; Yang XD
Oncotarget; 2016 Jun; 7(25):38257-38269. PubMed ID: 27203221
[TBL] [Abstract][Full Text] [Related]
2. A dual-targeting DNA tetrahedron nanocarrier for breast cancer cell imaging and drug delivery.
Liu X; Wu L; Wang L; Jiang W
Talanta; 2018 Mar; 179():356-363. PubMed ID: 29310244
[TBL] [Abstract][Full Text] [Related]
3. Multifunctional Bioconjugate for Cancer Cell-Targeted Theranostics.
Du W; Yuan Y; Wang L; Cui Y; Wang H; Xu H; Liang G
Bioconjug Chem; 2015 Dec; 26(12):2571-8. PubMed ID: 26580576
[TBL] [Abstract][Full Text] [Related]
4. PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells.
Tan L; Neoh KG; Kang ET; Choe WS; Su X
Macromol Biosci; 2011 Oct; 11(10):1331-5. PubMed ID: 21818856
[TBL] [Abstract][Full Text] [Related]
5. Specific targeting delivery to MUC1 overexpressing tumors by albumin-chitosan nanoparticles conjugated to DNA aptamer.
Esfandyari-Manesh M; Mohammadi A; Atyabi F; Nabavi SM; Ebrahimi SM; Shahmoradi E; Varnamkhasti BS; Ghahremani MH; Dinarvand R
Int J Pharm; 2016 Dec; 515(1-2):607-615. PubMed ID: 27989825
[TBL] [Abstract][Full Text] [Related]
6. Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro.
Hu Y; Duan J; Zhan Q; Wang F; Lu X; Yang XD
PLoS One; 2012; 7(2):e31970. PubMed ID: 22384115
[TBL] [Abstract][Full Text] [Related]
7. Anti-MUC1 Aptamer/Negatively Charged Amino Acid Dendrimer Conjugates for Targeted Delivery to Human Lung Adenocarcinoma A549 Cells.
Masuda M; Kawakami S; Wijagkanalan W; Suga T; Fuchigami Y; Yamashita F; Hashida M
Biol Pharm Bull; 2016; 39(10):1734-1738. PubMed ID: 27725454
[TBL] [Abstract][Full Text] [Related]
8. Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro.
Yu C; Hu Y; Duan J; Yuan W; Wang C; Xu H; Yang XD
PLoS One; 2011; 6(9):e24077. PubMed ID: 21912664
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapy of Colon Cancer by Aptamer-Guided Holliday Junctions Loaded with Doxorubicin.
Yao F; An Y; Li X; Li Z; Duan J; Yang XD
Int J Nanomedicine; 2020; 15():2119-2129. PubMed ID: 32280210
[TBL] [Abstract][Full Text] [Related]
10. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro.
Liu Z; Duan JH; Song YM; Ma J; Wang FD; Lu X; Yang XD
J Transl Med; 2012 Jul; 10():148. PubMed ID: 22817844
[TBL] [Abstract][Full Text] [Related]
11. MUC1 aptamer-targeted DNA micelles for dual tumor therapy using doxorubicin and KLA peptide.
Charbgoo F; Alibolandi M; Taghdisi SM; Abnous K; Soltani F; Ramezani M
Nanomedicine; 2018 Apr; 14(3):685-697. PubMed ID: 29317345
[TBL] [Abstract][Full Text] [Related]
12. Microenvironmental Control of MUC1 Aptamer-Guided Acid-Labile Nanoconjugate within Injectable Microporous Hydrogels.
Xu C; Han X; Jiang Y; Yuan S; Wu Z; Wu Z; Qi X
Bioconjug Chem; 2017 Oct; 28(10):2530-2537. PubMed ID: 28949511
[TBL] [Abstract][Full Text] [Related]
13. Anti-MUC1 aptamer: A potential opportunity for cancer treatment.
Nabavinia MS; Gholoobi A; Charbgoo F; Nabavinia M; Ramezani M; Abnous K
Med Res Rev; 2017 Nov; 37(6):1518-1539. PubMed ID: 28759115
[TBL] [Abstract][Full Text] [Related]
14. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo.
Bahreyni A; Alibolandi M; Ramezani M; Sarafan Sadeghi A; Abnous K; Taghdisi SM
Colloids Surf B Biointerfaces; 2019 Mar; 175():231-238. PubMed ID: 30537619
[TBL] [Abstract][Full Text] [Related]
15. SL2B aptamer and folic acid dual-targeting DNA nanostructures for synergic biological effect with chemotherapy to combat colorectal cancer.
Sun P; Zhang N; Tang Y; Yang Y; Chu X; Zhao Y
Int J Nanomedicine; 2017; 12():2657-2672. PubMed ID: 28435250
[TBL] [Abstract][Full Text] [Related]
16. Designer tridentate mucin 1 aptamer for targeted drug delivery.
Tan L; Gee Neoh K; Kang ET; Choe WS; Su X
J Pharm Sci; 2012 May; 101(5):1672-7. PubMed ID: 22383033
[TBL] [Abstract][Full Text] [Related]
17. Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas.
Ghasemi Z; Dinarvand R; Mottaghitalab F; Esfandyari-Manesh M; Sayari E; Atyabi F
Carbohydr Polym; 2015 May; 121():190-8. PubMed ID: 25659689
[TBL] [Abstract][Full Text] [Related]
18. MUC1 aptamer-conjugated mesoporous silica nanoparticles effectively target breast cancer cells.
Hanafi-Bojd MY; Moosavian Kalat SA; Taghdisi SM; Ansari L; Abnous K; Malaekeh-Nikouei B
Drug Dev Ind Pharm; 2018 Jan; 44(1):13-18. PubMed ID: 28832225
[TBL] [Abstract][Full Text] [Related]
19. The application of aptamer 5TR1 in triple negative breast cancer target therapy.
Luo S; Wang S; Luo N; Chen F; Hu C; Zhang K
J Cell Biochem; 2018 Jan; 119(1):896-908. PubMed ID: 28671278
[TBL] [Abstract][Full Text] [Related]
20. Targeted imaging of breast cancer cells using two different kinds of aptamers -functionalized nanoparticles.
Mohammadinejad A; Taghdisi SM; Es'haghi Z; Abnous K; Mohajeri SA
Eur J Pharm Sci; 2019 Jun; 134():60-68. PubMed ID: 30970280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
